CARMIEL, Israel, April 18, 2017 (GLOBE NEWSWIRE) — Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today new, promising results from a preclinical trial conducted in... Read More →

– Event to bring together worldwide experts to share and discuss latest research that is influencing treatment and management of patients with acute leukemia   –... Read More →

ROCKVILLE, Md., April 18, 2017 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced the publication of a new study... Read More →

Iclaprim met the primary endpoint Iclaprim was well tolerated in the study Data from the second Phase 3 ABSSSI Trial, REVIVE-2, expected in the second half of... Read More →

Media release (PDF).pdf Designation prioritizes investigational CTL019 (tisagenlecleucel) as a potential treatment for adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)  R/r DLBCL,... Read More →

BASEL, Switzerland and CAMBRIDGE, Mass. and DURHAM, N.C., April 17, 2017 (GLOBE NEWSWIRE) — CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based... Read More →

Bethlehem, PA, April 17, 2017 (GLOBE NEWSWIRE) — Fuisz today announced the filing of a patent application with the United States Patent & Trademark Office... Read More →

Company also Announces Discontinuation of Brontictuzumab Phase 1b Study OncoMed Management to Host Conference Call/Webcast at 8:30 a.m. ET/5:30 a.m. PT to Review Top-line Results... Read More →

VIENNA, Austria, April 17, 2017 (GLOBE NEWSWIRE) — Leading malaria researcher Tom van Gool’s presentation at the 27th European Congress for Clinical Microbiology and Infectious... Read More →

SALT LAKE CITY, April 17, 2017 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that new... Read More →